{
  "ticker": "BB1",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963300",
  "id": "02963300",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250630",
  "time": "0831",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250630/pdf/06l7g207m6t5gk.pdf",
  "summary": "- **US Ethics Approval Obtained**: IRB approval secured from WCG for main phase of FDA 510(k) diagnostic trial for BlinkLab Dx 1.  \n- **Trial Scope**: Multi-site US study with up to 1,000 participants, focusing on autism diagnosis.  \n- **Next Steps**: Onboarding \u22658 clinical sites; pilot study results expected Q3 2025.  \n- **Regulatory Advantage**: Trial classified as minimally invasive, exempt from most IDE requirements, streamlining progress.  \n\n*No capital raising, financials, or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 1546,
    "completion_tokens": 121,
    "total_tokens": 1667,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-29T22:39:24.753610"
}